AVR 0.58% $19.00 anteris technologies ltd

Ann: Key Animal Study for EFS Submission Completed, page-2

  1. 3,541 Posts.
    lightbulb Created with Sketch. 150
    Last piece from the announcement;
    'The early review of this data is consistent with observations from previous studies. Once the data
    is formally analysed it will be submitted to the FDA in the final dossier seeking approval to
    commence the first in human TAVR study'

    How long before we get the go-ahead to start Human Trials....what we've been waiting for.
    Great times ahead.

    Cheers Dabrru
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.